• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The risk of stroke recurrence in patients with atrial fibrillation and reduced ejection fraction.心房颤动伴射血分数降低患者的卒中复发风险。
Eur Stroke J. 2023 Sep;8(3):731-737. doi: 10.1177/23969873231177625. Epub 2023 May 30.
2
Risk of recurrent stroke in patients with atrial fibrillation treated with oral anticoagulants alone or in combination with anti-platelet therapy.口服抗凝药物单独或联合抗血小板治疗的心房颤动患者的卒中复发风险。
Eur Stroke J. 2023 Sep;8(3):722-730. doi: 10.1177/23969873231183211. Epub 2023 Jul 17.
3
Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.利伐沙班与阿哌沙班治疗房颤患者的主要缺血或出血事件的相关性。
JAMA. 2021 Dec 21;326(23):2395-2404. doi: 10.1001/jama.2021.21222.
4
Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study.急性缺血性卒中合并心房颤动患者的早期复发与脑出血:抗凝治疗及其时机的影响:RAF研究
Stroke. 2015 Aug;46(8):2175-82. doi: 10.1161/STROKEAHA.115.008891. Epub 2015 Jun 30.
5
Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study.非维生素 K 拮抗剂口服抗凝剂治疗急性卒中老年患者中复发性缺血性卒中和出血:RENO-EXTEND 研究。
Stroke. 2022 Aug;53(8):2620-2627. doi: 10.1161/STROKEAHA.121.038239. Epub 2022 May 11.
6
Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk.高危老年房颤患者出血风险增加时用直接口服抗凝剂预防卒中。
Eur Heart J Qual Care Clin Outcomes. 2022 Oct 26;8(7):730-738. doi: 10.1093/ehjqcco/qcab076.
7
Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.非瓣膜性心房颤动患者接受口服抗凝剂治疗的风险水平和不良临床结局。
JAMA Netw Open. 2022 Aug 1;5(8):e2229333. doi: 10.1001/jamanetworkopen.2022.29333.
8
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).心房颤动抗凝治疗患者血栓栓塞和出血事件的风险因素:前瞻性、多中心观察性预防血栓栓塞事件-心房颤动欧洲登记研究(PREFER in AF)。
BMJ Open. 2019 Mar 30;9(3):e022478. doi: 10.1136/bmjopen-2018-022478.
9
Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.颅内出血史的房颤患者中,华法林与非维生素 K 拮抗剂口服抗凝剂使用与缺血性卒、大出血和其他不良事件的关联。
JAMA Netw Open. 2020 Jun 1;3(6):e206424. doi: 10.1001/jamanetworkopen.2020.6424.
10
Clinical outcomes of left atrial appendage occlusion versus direct oral anticoagulation in patients with atrial fibrillation and prior ischemic stroke: A propensity-score matched study.经倾向性评分匹配研究:左心耳封堵术与直接口服抗凝药治疗房颤合并既往缺血性卒中患者的临床结局。
Int J Cardiol. 2022 Sep 15;363:56-63. doi: 10.1016/j.ijcard.2022.06.065. Epub 2022 Jun 30.

引用本文的文献

1
Heart failure, recurrent vascular events and death in patients with ischemic stroke-results of the MonDAFIS study.缺血性脑卒中患者的心力衰竭、再发性血管事件和死亡——MonDAFIS 研究结果。
Intern Emerg Med. 2024 Aug;19(5):1247-1254. doi: 10.1007/s11739-024-03594-8. Epub 2024 Apr 15.
2
Detection of microemboli in patients with acute ischaemic stroke and atrial fibrillation suggests poor functional outcome.检测急性缺血性脑卒中合并心房颤动患者的微栓子提示预后不良。
Eur Stroke J. 2024 Jun;9(2):409-417. doi: 10.1177/23969873231220508. Epub 2023 Dec 27.

本文引用的文献

1
Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study.非维生素 K 拮抗剂口服抗凝剂治疗急性卒中老年患者中复发性缺血性卒中和出血:RENO-EXTEND 研究。
Stroke. 2022 Aug;53(8):2620-2627. doi: 10.1161/STROKEAHA.121.038239. Epub 2022 May 11.
2
Atrial fibrillation-induced tachycardiomyopathy and heart failure: an underappreciated and elusive condition.心房颤动诱发的心动过速性心肌病与心力衰竭:一种未得到充分认识且难以捉摸的病症。
Heart Fail Rev. 2022 Nov;27(6):2119-2135. doi: 10.1007/s10741-022-10221-1. Epub 2022 Mar 23.
3
Characteristics and long-term prognosis of patients with reduced, mid-range, and preserved ejection fraction: A systemic review and meta-analysis.射血分数降低、中间范围和保留的患者的特征和长期预后:系统评价和荟萃分析。
Clin Cardiol. 2022 Jan;45(1):5-17. doi: 10.1002/clc.23754. Epub 2022 Jan 18.
4
Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes.急性缺血性卒中合并心房颤动患者口服抗凝剂起始时机的比较:后循环卒中与前循环卒中
Eur Stroke J. 2020 Dec;5(4):374-383. doi: 10.1177/2396987320937116. Epub 2020 Jul 22.
5
Heart Failure With Reduced Ejection Fraction: A Review.射血分数降低型心力衰竭:综述。
JAMA. 2020 Aug 4;324(5):488-504. doi: 10.1001/jama.2020.10262.
6
Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.卒中或短暂性脑缺血发作合并非瓣膜性心房颤动患者预防卒中及其他血栓栓塞事件的二级预防抗栓治疗:欧洲卒中组织指南
Eur Stroke J. 2019 Sep;4(3):198-223. doi: 10.1177/2396987319841187. Epub 2019 Apr 9.
7
Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study.急性缺血性脑卒中合并心房颤动患者应用新型口服抗凝药物(NOACs)后早期复发和大出血的研究(RAF-NOACs 研究)。
J Am Heart Assoc. 2017 Nov 29;6(12):e007034. doi: 10.1161/JAHA.117.007034.
8
Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.射血分数保留、中间范围和降低的心衰伴发的心房颤动。
JACC Heart Fail. 2017 Aug;5(8):565-574. doi: 10.1016/j.jchf.2017.05.001. Epub 2017 Jul 12.
9
Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.新型口服抗凝剂在房颤合并心力衰竭患者中的疗效和安全性:一项荟萃分析。
JACC Heart Fail. 2016 Nov;4(11):870-880. doi: 10.1016/j.jchf.2016.07.012. Epub 2016 Sep 7.
10
Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes.射血分数降低与保留型心力衰竭所致心房颤动:死亡及不良结局的系统评价与荟萃分析
Int J Cardiol. 2016 Jan 15;203:660-6. doi: 10.1016/j.ijcard.2015.10.220. Epub 2015 Oct 28.

心房颤动伴射血分数降低患者的卒中复发风险。

The risk of stroke recurrence in patients with atrial fibrillation and reduced ejection fraction.

出版信息

Eur Stroke J. 2023 Sep;8(3):731-737. doi: 10.1177/23969873231177625. Epub 2023 May 30.

DOI:10.1177/23969873231177625
PMID:37249094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10472961/
Abstract

BACKGROUND

Atrial fibrillation (AF) and congestive heart failure often coexist due to their shared risk factors leading to potential worse outcome, particularly cerebrovascular events. The aims of this study were to calculate the rates of ischemic and severe bleeding events in ischemic stroke patients having both AF and reduced ejection fraction (rEF) (⩽40%), compared to ischemic stroke patients with AF but without rEF.

METHODS

We performed a retrospective analysis that drew data from prospective studies. The primary outcome was the composite of either ischemic (stroke or systemic embolism), or hemorrhagic events (symptomatic intracranial bleeding and severe extracranial bleeding).

RESULTS

The cohort for this analysis comprised 3477 patients with ischemic stroke and AF, of which, 643 (18.3%) had also rEF. After a mean follow-up of 7.5 ± 9.1 months, 375 (10.8%) patients had 382 recorded outcome events, for an annual rate of 18.0%. While the number of primary outcome events in patients with rEF was 86 (13.4%), compared to 289 (10.2%) for the patients without rEF; on multivariable analysis rEF was not associated with the primary outcome (OR 1.25; 95% CI 0.84-1.88). At the end of follow-up, 321 (49.9%) patients with rEF were deceased or disabled (mRS ⩾3), compared with 1145 (40.4%) of those without rEF; on multivariable analysis, rEF was correlated with mortality or disability (OR 1.35; 95% CI 1.03-1.77).

CONCLUSIONS

In patients with ischemic stroke and AF, the presence of rEF was not associated with the composite outcome of ischemic or hemorrhagic events over short-term follow-up but was associated with increased mortality or disability.

摘要

背景

心房颤动(AF)和充血性心力衰竭常因共同的危险因素而同时存在,导致潜在的预后更差,尤其是脑血管事件。本研究的目的是计算伴有射血分数降低(rEF)(≤40%)的缺血性脑卒中患者与仅存在 AF 而无 rEF 的缺血性脑卒中患者发生缺血性和严重出血事件的发生率。

方法

我们进行了一项回顾性分析,该分析从前瞻性研究中提取数据。主要结局是缺血性(卒中和系统性栓塞)或出血性事件(症状性颅内出血和严重颅外出血)的复合结局。

结果

本分析队列包括 3477 例伴有 AF 的缺血性脑卒中患者,其中 643 例(18.3%)同时存在 rEF。在平均 7.5±9.1 个月的随访后,375 例(10.8%)患者发生了 382 例记录的结局事件,年发生率为 18.0%。虽然 rEF 患者的主要结局事件数量为 86 例(13.4%),但无 rEF 患者为 289 例(10.2%);多变量分析显示 rEF 与主要结局无相关性(OR 1.25;95% CI 0.84-1.88)。随访结束时,321 例(49.9%)rEF 患者死亡或残疾(mRS≥3),而无 rEF 患者为 1145 例(40.4%);多变量分析显示,rEF 与死亡率或残疾相关(OR 1.35;95% CI 1.03-1.77)。

结论

在伴有缺血性脑卒中及 AF 的患者中,rEF 的存在与短期随访期间缺血性或出血性复合结局无关,但与死亡率或残疾增加相关。